Terry, I have a question about us licensing and our a patent in regards to Recaf. Read this................. --------------------------------------------------------------------------------
(OTC BB: RJVN) Announces Cancer Treatment Therapy Advances Using BioCurex RECAF Technology Through A Licensing Agreement with its BioKinetix (acquisition underway).
Thursday December 19, 10:00pm ET
http://finance.yahoo.com/q?s=rjvn.ob&d=t RJV Network, Inc. (OTC BB:RJVN.OB - News), a Nevada corporation, is in the process of acquiring BioKinetix Research Inc. BELLEVUE, Wash., and announces further developments of the combined Company revolutionary cancer treatment therapy, now just months away from formal market testing to begin.
BioCurex Inc. announced on December 16th that it has completed a licensing agreement with BioKinetix (being acquired by OTC BB: RJVN) to use BioCurex's RECAF technology. The license will allow BioKinetix to use its InNexus Super Antibody platform technology to create therapeutic antibodies; then combining RECAF antibodies with RJVN Super Antibody technology could give BioKinetix the potential to create both highly potent therapeutic antibodies, as well as vaccines to immunize against the RECAF receptor, creating a highly effective treatment for most cancers as agreed upon by many world renowned molecular biologists, including Dr. John Todd of RJVN BioKinetix.
BioCurex, Inc. is a biotechnology company that is developing products based on patented / proprietary technology in the areas of cancer diagnosis, tumor imaging ad therapeutics. The technology identifies a cancer marker known as RECAF(tm), which is found on malignant cells from a variety of cancer types but absent in most normal or benign cells. Detailed information about BioCurex may be obtained from their website at biocurex.com .
Created over ten years of expensive research and development, RECAF technology is able to effectively locate molecules (markers) that are present on active cancer cells, but not on healthy cells. The combination of these two technologies gives BioKinetix the potential to create a series of therapeutic products that may treat most cancers. The therapeutics to be developed are monoclonal antibodies that mark growth factor receptor on cancer tissue. Combining RECAF antibodies with Super Antibody technology will give BioKinetix the potential to create both highly potent therapeutic antibodies, as well as vaccines to immunize against the RECAF receptor.
On behalf of the Board of Directors,
Mr. Edward Velton, President Contact: For RJV Network, Inc. Grant Young
Company Name----------------RJV Networks, Inc. Symbol----------------------RJVN Current Price---------------$0.10 52 Week High----------------$2.10 52 Week Low-----------------$0.10
Target $4 -to- $6 Q3/2003
Investment Highlights
RJVN projects it will be able to treat most cancers with its combined targeted therapy treatment which is based upon an astounding discovery by a molecular biologist at the Univ. of Michigan - The causal link to breast and most other malignancies and cancers in the protein Mammastatin.
RJVN has developed a series of cancer treatment therapies which utilize pan-cancer market antibodies. Antibody therapies do not create chemical toxicity and, as such, are fast tracked through the regulatory approval process. Using this approach, RJVN is targeted to enter testing for its products in six months.
RJVN's combination of two leading, well known technologies previously announced by BioCurex and InNexus Corp along with RJVN's key MAb protein replicating technology has allowed the Company to create a series of patented therapeutic products that many molecular biologists believe will treat most cancers.
RJVN's R&D and Management are led by Dr. John Todd, Dr. Charles Morgan (a world renowned molecular biologist and 5 other industry leading Dr's all with several years experience in bio-tech development. ................................................................................................................................................................................................ Everyone on this board don't get overly excited. This was dated 2003. However, I did a quick search on EDGAR under heading Recaf and Dec 27, 2007 Innexus was specific in saying they are using monoclonal antibiotics targeting the receptor for Recaf. What is up with this?